Huntington's disease (HD) could be a fatal genetic disease characterised by triad clinical symptoms of chorea, emotional distress, and psychological feature decline. Huntington malady (HD) could be a rare neurodegenerative disorder of the central system characterised by unwanted choreatic movements, behavioural and psychiatrical disturbances and dementedness. Prevalence within the population is calculable at 1/10,000-1/20,000. Mean age at onset of symptoms is 30-50 years. In some cases, symptoms begin before the age of twenty years with behavior disturbances and learning difficulties in class (Juvenile Huntington’s disease; JHD). The classic sign is chorea that delicately spreads to any or all muscles. There are a unit presently no malady modifying treatments so accessory and symptomatic management is that the mainstay of treatment. In recent years there are vital advances in understanding each the cellular pathology and also the macroscopical structural brain changes that occur because the malady progresses. Within the last decade there has been an outsized growth in potential therapeutic targets and clinical trials, maybe the foremost promising of those area unit. The rising therapies geared toward lowering levels of mutant huntingtin. Antisense oligonucleotide medical aid is one such approach with clinical trials presently afoot, this could bring United States of America one step nearer to treating and doubtless preventing this devastating condition.
Cite this article:
Bhoomij B. Moon, Girish D. Dahikar, Rajendra O. Ganjiwale. A Review on Huntington’s disease. Research J. Pharm. and Tech. 2020; 13(10):4990-4995. doi: 10.5958/0974-360X.2020.00874.4
Bhoomij B. Moon, Girish D. Dahikar, Rajendra O. Ganjiwale. A Review on Huntington’s disease. Research J. Pharm. and Tech. 2020; 13(10):4990-4995. doi: 10.5958/0974-360X.2020.00874.4 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-10-77
1. Wexler A, Wild EJ, Tabrizi SJ. George Huntington: a legacy of inquiry, empathy and hope. Brain. 2016 Jul 14;139(8):2326-33.
2. Buchake VV, Muthal AP, Saudagar RB, Bachhav RS. A Neurodegenerative Disorder-Alzheimer disease: A Treatise. Research Journal of Pharmacology and Pharmacodynamics. 2010;2(4):268-73.
3. Bruyn GW: Huntington’s chorea: historical, clinical and laboratory synopsis. In Handbook of Clinical Neurology. Volume 6. Edited by: Vinken PJ, Bruyn GW. Elsevier Amsterdam; 1968:298-378.
4. The bridge clinic, what are the signs and symptoms of huntingtons disease © Copyright 2019 Bridge Clinic RC Number: 296773Lipe H, Schultz A, Bird TD. Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. American journal of medical genetics. 1993 Dec 15;48(4):231-3.
5. Huntington's Disease Society of America, Quaid KA, Morris M. Reluctance to undergo predictive testing: the case of Huntington disease. American journal of medical genetics. 1993 Jan 1;45(1):41-5.
6. Jana U, Pal S, Mohanta GP, Manna PK, Manavalan R. Nanoparticles: A Potential Approach for Drug Delivery. Research Journal of Pharmacy and Technology. 2011;4(7):1016-9.
7. Gaikwad U, Parle M. Treatment for the management of Obsessive-Compulsive Disorder in Children: A Review. Research Journal of Pharmacy and Technology. 2010;3(1):66-8.
8. Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10: 83–98
9. Rosenblatt A, Ranen NG, Nance MA, Paulsen JS. A physician's guide to the management of Huntington's disease. Huntington’s Disease Society of America, New York. 1999.
10. Periyanayagam K, Gokila S, Balasubramaniam KG, Jagatheeswary PA, Suriakumar J, Parameshwari R. Protective Effect of the Leaves of Solanum torvums wartz on Drosophila melanogaster against β-Amyloid Induced Alzheimer Disease. Research Journal of Pharmacy and Technology. 2015;8(6):719-27.
11. Kamala M, Banu MS, Senthil R, Anand AV. Anti–Hyperglycemic and Anti–Hyperlipidemic Potentials of Psidium guajava Fruit Extract–a Review. Research Journal of Pharmacy and Technology. 2011;4(7):1033-6.
12. Kremer HP, Roos RA, Dingjan GM, Bots GT, Bruyn GW, Hofman MA: The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington’s disease. Neurosci Lett 1991, 132:101-4
13. Wee KW, Ilyas MN, Nodrin S, Zubaidi AB, Atif AB. Unique Alzheimer's Disease Challenges at less Urban Area: Case Reports in Malaysia. Research Journal of Pharmacy and Technology. 2018 Sep 1;11(9):4033-4.
14. Finkbeiner S. Huntington's disease. Cold Spring Harbor perspectives in biology. 2011 Jun 1;3(6): a007476.
15. Patra K, Shirolkar M, Childhood-onset (Juvenile) Huntington's disease: A rare case report. Journal of Pediatric Neurosciences 10, 276-279 (2015).
16. Shetty R, Udupa N, Mutalik S, Kulkarni V, Rao V. Mechanisms and Therapeutics of N-acetylcysteine: A Recent Update. Research Journal of Pharmacy and Technology. 2019;12(5):2584-8.
17. Shampo MA, Kyle RA, Steensma DP, “Alois Alzheimer Disease, in Mayo Clinic Proceedings Symptoms” 2013 Dec 1 (Vol. 88, No. 12, p. e155). Elsevier.
18. Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, McDowell B, Turner B. Depression and stages of Huntington’s disease. The Journal of neuropsychiatry and clinical neurosciences. 2005 Nov;17(4):496-502.
19. Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group: Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008, 79:874-80.
20. Mayberg, Helen. "Depression and frontal-subcortical circuits: Focus on prefrontal-limbic interactions." (2001).
21. Swathypriyadharsini P, Premalatha K. Particle Swarm Optimization for Triclustering High Dimensional Microarray Gene Expression Data. Research Journal of Pharmacy and Technology. 2019;12(5):2222-8.
22. Dunn C. Huntington's Disease--A Review. The Kabod. 2016;2(2):9.
23. Mahalingam S, Levy LM. Genetics of huntington disease. American journal of neuroradiology. 2014 Jun 1;35(6):1070-2.
24. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. Journal of Neuroscience. 1999 Feb 1;19(3):964-73.
25. Kahlem P, Green H, Djian P. Transglutaminase action imitates Huntington’s disease: selective polymerization of huntingtin containing expanded polyglutamine. Mol. Cell 1998; 1:595– 601.
26. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156: 1279–1281.
27. Sanmugam K. Depression is a risk factor for Alzheimer disease-review. Research Journal of Pharmacy and Technology. 2015 Aug 1;8(8):1056.
28. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48: 358–362.
29. Sivakumar J, Sundaram CS, Krishnasamy L, Rao UM. Relative Bioremediation of Used engine oil Contaminated soil from an Industrialised area by Various microbes. Research Journal of Pharmacy and Technology. 2019;12(1):331-8.
30. Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014; 11(1): 153-160.
31. Garcia M, Downs J, Russell A, Wang W. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet journal of rare diseases. 2018 Dec;13(1):202.